KKStock Ro, a privately held telehealth platform, is launching a feature on its website that it says will provide customers with real-time information on supplies of popular GLP-1 drugs used for weight loss from Eli Lilly ( NYSE: LLY ) and Novo Nordisk ( NVO ). The GLP-1 Supply Tracker will use "proprietary, nationwide supply data as well as user-generated reports along with the latest information from the FDA's Drug Shortage List." Due to their popularity, Eli Lilly's Zepbound (tirzepatide) and Novo's Wegovy (semaglutide) are in short supply in many parts of the U.
S. The drugs are also marketed by each company for type 2 diabetes under the names, respectively, Mounjaro and Ozempic. Users are able to use the tracker to add information on a pharmacy's stock -- or shortage -- of a GLP-1 drug.
Patients can also sign up to receive email alerts when supply is available in their area or when the FDA makes changes to a GLP-1 shortage status. More on Eli Lilly, Novo Nordisk Eli Lilly: Addressing Supply Challenges Should Accelerate Growth SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Novo Nordisk: The Market Is Right, Don't Fight Against It SA Asks: Who will launch the next big weight-loss drug? Novo Nordisk: Considerable Growth Beyond Ozempic.
